Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Increases By 288.5%

Evoke Pharma, Inc. (NASDAQ:EVOK) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 101,000 shares, an increase of 288.5% from the October 15th total of 26,000 shares. Currently, 7.4% of the company’s stock are short sold. Based on an average daily volume of 423,900 shares, the days-to-cover ratio is presently 0.2 days.

Evoke Pharma Stock Performance

NASDAQ EVOK traded down $0.38 on Tuesday, reaching $5.00. The company had a trading volume of 73,934 shares, compared to its average volume of 128,880. The company’s fifty day moving average is $5.06 and its 200-day moving average is $5.52. The firm has a market capitalization of $4.10 million, a price-to-earnings ratio of -0.49 and a beta of 0.36. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $17.88.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 514.74%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Evoke Pharma in a research note on Tuesday. They issued a “sell” rating on the stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.